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BACKGROUND: This study investigated the relationship of obesity, insulin resistance, inflammation and angiogenesis with cancer
progression and survival in a colorectal cancer cohort.
METHODS: Clinical and pathological data, along with anthropometric and follow-up data, were collected from 344 consecutive
colorectal cancer patients. Serum samples at diagnosis were analysed by immunoassay for adiponectin, C-reactive protein (CRP),
vascular endothelial growth factor-A (VEGF-A), angiopoietin-2 (Ang-2), insulin-like growth factor-1 (IGF-1), insulin and C-peptide.
RESULTS: Serum Ang-2 and VEGF-A levels increased with tumour T stage (P¼0.007 and P¼0.025, respectively) and N stage (P¼0.02
and P¼0.03, respectively), and correlated with CRP levels (r¼0.43, Po0.001 and r¼0.23, Po0.001, respectively).
Angiopoietin-2 correlated with C-peptide (r¼0.14, P¼0.007) and VEGF-A with IGF-1 in males (r¼0.25, P¼0.001). Kaplan–
Meier analysis showed that patients with high serum levels of CRP and Ang-2 had significantly reduced survival (both Pp0.001). After
adjusting for tumour stage and age, Ang-2 remained a significant predictor of survival. The CRP levels were inversely associated with
survival in American Joint Committee on Cancer stage II patients (P¼0.038), suggesting that CRP could be used to support treatment
decisions in this subgroup. Serum markers and anthropometric measures of obesity correlated with each other, but not with survival.
CONCLUSION: Our study supports the concept that obesity-related inflammation, rather than obesity itself, is associated with colorectal
cancer progression and survival. The study confirms serum Ang-2 as a predictive marker for outcome of colorectal cancer.
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Colorectal cancer is the third most common cancer in women and
the fourth most common cancer in men worldwide (Parkin et al,
2005). It is second only to lung cancer as a cause of cancer deaths
in New Zealand (Frizelle, 2009), and New Zealand women have
both the highest incidence and highest mortality from colorectal
cancer in the world (Center et al, 2009).
Epidemiological studies have shown that the risk for colorectal
cancer development is strongly related to obesity and the
metabolic syndrome (Moghaddam et al, 2007; Pais et al, 2009).
The mechanism underlying this association is not completely
understood, but obesity-induced insulin resistance, adipokine
levels and obesity-related inflammation are all important factors
(Sandhu et al, 2002; Giovannucci, 2007; Birmingham et al, 2009;
Gonullu et al, 2009), implicating insulin resistance and alterations
in the insulin – insulin-like growth factor-1 (IGF-1) axis as the
main driving forces (Komninou et al, 2003; Giovannucci, 2007).
Both insulin and IGF-1 are potent mitogens that promote
colorectal cancer cell growth and survival in vitro (Komninou
et al, 2003), and elevated blood levels of IGF-1 and insulin are
associated with increased risk of developing colorectal cancer
(Komninou et al, 2003).
Angiogenesis, the formation of new blood vessels, has a vital
function in tumour growth and spread (Rmali et al, 2006), and
IGF-1 and insulin induce angiogenesis in vitro and in vivo
(Reinmuth et al, 2002). Levels of the main angiogenic factors,
vascular endothelial growth factor-A (VEGF-A) (Cao et al, 2009)
and angiopoietin-2 (Ang-2) (Chung et al, 2006), are correlated with
tumour progression and patient outcome in colorectal cancer.
Despite support for the importance of obesity and metabolic
syndrome as risk factors for colorectal cancer development, data
are equivocal for their effects on colorectal cancer progression and
outcome (Trevisan et al, 2001; Dignam et al, 2006; Reeves et al,
2007; Meyerhardt et al, 2008; Moon et al, 2008; Wolpin et al, 2009).
Several studies found worse survival and increased recurrence for
patients with insulin resistance or high body mass index (BMI)
(Trevisan et al, 2001; Dignam et al, 2006; Moon et al, 2008; Wolpin
et al, 2009), while other studies reported no significant relationship
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s(Meyerhardt et al, 2003; Reeves et al, 2007). Obesity influences
duration of surgery and post-surgery complications in colorectal
cancer patients (Tsujinaka et al, 2008; Merkow et al, 2009), and
alters the response of breast cancer patients to chemotherapy
(Litton et al, 2008).
In this study, we investigated the relationship of obesity, insulin
resistance and inflammation with colorectal cancer progression
and survival in a New Zealand colorectal cancer cohort. We
propose that obesity-related chronic hyperinsulinemia and
insulin resistance promote a pro-inflammatory and pro-angiogenic
environment that stimulates tumour growth and metastasis, and
leads to poor survival.
MATERIALS AND METHODS
Patients
The study cohort comprised consecutive patients undergoing
surgery for adenocarcinoma of the colon or upper rectum at
Christchurch Hospital between 28 July 1998 and 28 April 2008. All
participants had given written informed consent for collection of
tumour tissue and blood for research, and samples were obtained
after approval from the Cancer Society Tissue Bank (CSTB),
Christchurch. The study was approved by the Upper South
Ethics Committee (approval number: URB/08/02/006). Stage IV
patients (n¼14) were included, but were highly selected in having
low volume metastatic disease, or undergoing colectomy at the
time of emergency presentation with obstruction or perforation.
All analyses were performed both with this group of stage IV
patients included and excluded, and as results were similar, data
are presented with stage IV patients included.
Patients were treated according to standard guidelines with pre-
operative staging by blood tests forf u l lb l o o dc o u n t ,l i v e rf u n c t i o n
tests, chest X-ray and computerised tomography of abdomen and
pelvis. In a few cases, the liver was imaged by ultrasound or magnetic
resonance imaging (MRI). Patients with rectal cancer also underwent
MRI of the pelvis, but were then excluded from this study if they were
treated with pre-operative radiation with or without concurrent
chemotherapy. The surgical specimens were analysed pathologically
by a specialist group of pathologists, although synoptic reporting was
only formally introduced in 2005. Staging was by American Joint
Committee on Cancer (AJCC) TNM classification (Greene et al, 2002).
Post-operative adjuvant chemother a p yw a so f f e r e dt op a t i e n t sw i t h
nodes involved and also to node-negative patients with adverse
features including perforation, vascular or lymphatic invasion and T4
tumours. Either intravenous weekly 5-fluorouracil with leucovorin, or
capecitabine, or an oxaliplatin combination was administered. Patients
were followed up routinely by the colorectal service at Christchurch
Hospital with 6-monthly clinical assessment and blood carcino-
embryonic antigen (CEA), with an annual and then 3-yearly
colonoscopy, with imaging when indicated on clinical grounds or
by CEA rise.
Sample collection and storage
Blood samples were collected into plain tubes (BD-vacutainer,
Franklin Lakes, NJ, USA) from patients on admission to
Christchurch Hospital, before colectomy. Blood samples were
centrifuged (1800r.p.m. 10min), and the serum aliquoted and
stored at  801C until used in immunoassays.
Immunoassays
Commercially available Quantikine human ELISA kits (R&D
systems, Minneapolis, MN, USA) for adiponectin, high sensi-
tivity-C-reactive protein (CRP), VEGF-A, Ang-2 and IGF-1 and
human ELISA kit (Millipore, Billerica, MA, USA) for insulin and
C-peptide were used to measure the levels of proteins in
patient serum samples. All ELISAs were performed following
manufacturers’ protocols, with samples assayed in duplicate with
appropriate standards as controls.
Data collection
Demographic and clinical data, along with the pathology report for
each patient, were prospectively recorded in the CSTB database.
Baseline staging, weight, height, body surface area and BMI were
obtained from medical records, together with follow-up informa-
tion. The BMI was defined as is standard with o18.5kgm
–2
underweight; 18.5–24kgm
–2 normal; 25–29kgm
–2 overweight;
X30kgm
–2 obese and X35kgm
–2 morbidly obese. Diabetes was
recorded from the clinical records, but in addition blood glucose
levels were checked to disclose previously undiagnosed type 2
diabetes. Follow-up was recorded until 31 August 2009.
Statistical analysis
Statistical analysis was performed using SPSS version 16 (SPSS
Inc., Chicago, IL, USA, 16). Frequency and descriptive statistics
were used to describe the cohort. Pearson’s product-moment
correlations were used to analyse relationships among serum
markers, and between serum markers and tumour size, depth and
percentage of bowel circumference. Independent-sample t-tests
were used to compare the levels of serum markers in patients
with or without diabetes, lymphatic and vascular invasion,
perineural invasion, necrosis or lymph nodes metastasis. One-
way analysis of variance and linear test for trend were used to
compare the levels of serum markers across tumour stages and
grade. Both Kaplan–Meier and Cox regression analyses were
performed to analyse patient overall survival. Medians were used
to divide continuous data into groups for Kaplan–Meier analysis,
with standard cut points for BMI. In Cox regression analysis,
tumour stage was analysed as a categorical variable, and age, BMI
and serum markers as continuous variables. For the continuous
variables, hazard ratios were estimated using the following units:
100 units of VEGF-1, 1000 units of Ang-2, 1 unit of CRP, insulin,
C-peptide and BMI, 10 units of IGF-1 and per decade of age.
Predictors were entered either on their own, or jointly; stepwise
procedures were not used.
RESULTS
Colorectal cancer patients
The study cohort of 344 patients included 173 males and 171
females. Individuals ranged in age from 31 to 91 years of age
(mean¼71, median¼73) with 66% of patients aged between 60
and 80 years (Table 1). Only six females were o50 years of age,
hence assumed pre-menopausal. Twenty per cent were AJCC stage
I, 42% AJCC stage II, 34% stage III and 4% stage IV. Vascular or
lymphatic invasion was identified in 101 out of 337 tumours (30%)
and perineural invasion in 17 out of 159 tumours (11%), where
these were recorded. Twenty-eight individuals (8.1%) had a
diagnosis of type 2 diabetes mellitus.
The BMI decreased with advancing age, with no difference by
gender (Table 2). Only 2.2% of patients were underweight, with
27.7% normal weight, 45% overweight and 25.1% obese including
6.9% morbidly obese. This distribution reflects the background
New Zealand population (Ministry of Health, 2008).
Clinicopathological and serum factors
Serum levels of the angiogenic factors VEGF-A and Ang-2, and the
inflammatory factor CRP, according to clinicopathological features
are shown in Table 1. Data for the metabolic factors adiponectin,
IGF-1, insulin and C-peptide are available in Table 2.
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sThe VEGF-A levels were significantly higher at more advanced
T (tumour) stage (P¼0.025) and N (nodal) stage (P¼0.034), but
not AJCC stage (P¼0.07), as well as when lymphatic and vascular
invasion was present (P¼0.02). Angiopoietin-2 levels increased
with age (P¼0.02), more advanced T stage (P¼0.007) and N stage
(P¼0.02), but did not significantly correlate with AJCC stage
(P¼0.09). Angiopoietin-2 levels were higher when tumour
necrosis was present (P¼0.01), but necrosis data was missing in
48% of cases. The CRP levels increased with tumour AJCC stage
(Po0.001), T stage (Po0.001) and higher grade (P¼0.004), as well
as with increased tumour necrosis (P¼0.002). Levels of Ang-2 and
CRP were significantly higher in women compared with men
(P¼0.001 and Po0.001, respectively). Adiponectin levels
increased with age (P¼0.005), were higher in the absence of
perineural invasion (P¼0.03), although data were not available for
all patients. Adiponectin levels were higher in women (Po0.001)
and IGF-1 levels were higher in men (Po0.001).
Surrogate markers of obesity
The anthropometric measure BMI was positively correlated with
serum levels of insulin (r¼0.21, Po0.001) and C-peptide (r¼0.27,
Table 1 Serum angiogenic and inflammatory factors according to clinicopathological features in colorectal cancer patients
CRP (lgml
–1) VEGF-A (pgml
–1) Ang-2 (pgml
–1)
Total N Mean Standard deviation P-value Mean Standard deviation P-value Mean Standard deviation P-value
Gender (N total¼344)
Female 171 5.44 3.05 o0.001
a 432 375 0.084
a 3050 1501 0.001
a
Male 173 4.02 3.07 364 345 2536 1311
Age groups (N total¼344)
31–50 13 3.52 2.42 275 210 2591 2413
51–60 28 4.53 3.14 0.030
b 430 417 0.732
b 2061 854 0.004
b
61–70 102 4.12 3.05 0.026
c 398 370 0.425
c 2600 1306 0.022
c
71–80 146 4.99 3.12 409 343 2928 1482
81–91 55 5.55 3.28 379 394 3206 1287
AJCC (N total¼343)
I 69 3.20 2.57 367 332 2637 1501
IIA 115 5.00 3.14 323 263 2674 1301
IIB 29 5.50 3.48 o0.001
b 495 450 0.021
b 2972 1189 0.258
b
IIIA 9 4.45 3.42 o0.001
c 309 181 0.066
c 2649 1344 0.093
c
IIIB 71 4.85 3.07 441 430 2766 1357
IIIC 36 5.05 3.16 537 402 3331 1970
IV 14 7.38 2.08 459 469 3057 1207
T stage (N total¼342)
T1 28 3.18 2.67 246 267 2369 1064
T2 59 3.71 2.77 o0.001
b 440 359 0.064
b 2776 1583 0.007
b
T3 182 4.92 3.08 o0.001
c 388 362 0.025
c 2664 1278 0.007
c
T4 73 5.64 3.38 447 383 3276 1672
N stage (N total¼337)
N0 214 4.54 3.17 361 320 2709 1357
N1 79 4.86 3.01 0.181
b 432 439 0.061
b 2789 1325 0.069
b
N2 44 5.48 3.14 0.07
c 488 387 0.034
c 3267 1872 0.021
c
Grade (N total¼245)
1 8 2.69 1.89 0.001
b 566 412 0.094
b 2552 865 0.087
b
2 176 4.46 3.03 0.004
c 376 358 0.335
c 2719 1412 0.245
c
3 58 5.91 3.33 467 403 3194 1716
Lymph/vascular invasion (N total¼337)
No 236 4.49 3.01 0.102
a 354 301 0.016
a 2685 1268 o0.001
a
Yes 101 5.14 3.42 469 431 3053 1754
Perineural invasion (N total¼159)
No 135 4.50 3.29 0.331
a 461 366 0.487
a 2877 1522 0.805
a
Yes 17 5.32 3.14 396 330 2977 1869
Necrosis (N total¼180)
No 142 4.34 3.01 0.002
a 357 354 0.559
a 2536 1101 0.012
a
Yes 38 6.12 3.35 395 351 3084 1463
Lymphocytic infiltrate (N total¼267)
No 92 4.69 3.45 428 343 2738 1365
1 112 5.02 2.99 0.270
b 360 321 0.192
b 2728 1340 0.589
b
2 49 4.21 3.02 0.153
c 327 263 0.126
c 2610 1411 0.176
c
3 14 3.64 2.49 296 300 2246 701
Abbreviations: AJCC¼American Joint Committee on Cancer; Ang-2¼angiopoietin-2; ANOVA¼analysis of variance; CRP¼C-reactive protein; VEGF-A¼vascular endothelial
growth factor-A.
aIndependent-samples t-test.
bOne-way ANOVA.
cTest for linear trend.
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adiponectin (r¼ 0.32, Po0.001) (Table 3). Insulin showed a
positive correlation with C-peptide (r¼0.63, Po0.001), as
expected, and IGF-1 was correlated with both insulin (r¼0.14,
P¼0.01) and C-peptide (r¼0.14, P¼0.01). Serum adiponectin
showed an inverse correlation with IGF-1, insulin and C-peptide
(r¼ 0.21, Po0.001; r¼ 0.018, P¼0.001; r¼ 0.014, P¼0.01,
respectively).
Obesity, inflammation and angiogenic factors
Serum levels of the angiogenic proteins, Ang-2 and VEGF-A, were
correlated (r¼0.19, Po0.001) (Table 3). There was a positive
correlation between serum CRP and both VEGF-A (r¼0.23,
Po0.0001) and Ang-2 (r¼0.43, Po0.001). Serum levels of Ang-2
and C-peptide were positively correlated (r¼0.14, P¼0.007).
Serum VEGF-A was positively correlated with IGF-1 in males
(r¼0.25, P¼0.001), and a similar trend was observed for the
whole cohort (r¼0.10, P¼0.066; Table 3). Serum CRP levels
showed a negative association with IGF-1 (r¼ 0.18, P¼0.001).
Neither VEGF-A nor Ang-2 was associated with BMI or serum
adiponectin levels (P40.05).
Survival analysis
During the 10 years of follow-up time, 91 patients died from all
causes in the study cohort, with median survival not reached.
Eleven of the 14 patients with stage IV disease had died. Kaplan–
Meier survival analysis showed that patients with high serum levels
of CRP (Po0.001; P¼0.01 excluding stage IV) and Ang-2
Table 2 Obesity-related factors according to clinicopathological features in colorectal cancers patients
Adiponectin (ngml
–1) IGF-1 (ngml
–1) Insulin (lUml
–1) C-peptide (lgml
–1)B M I
Total
N Mean
Standard
deviation P-value Mean
Standard
deviation P-value Mean
Standard
deviation P-value Mean
Standard
deviation P-value Mean
Standard
deviation P-value
Gender (N total¼344)
Female 171 10213 6514 o0.001
a 82.04 30.56 o0.001
a 12.94 23.46 0.106
a 4.41 3.51 0.128
a 27.45 6.05 0.745
a
Male 173 7037 5107 104.15 36.83 17.07 23.82 5.01 3.82 27.64 4.64
Age groups (N total¼344)
31–50 13 6668 5822 99.76 41.46 24.18 32.41 4.26 2.96 28.87 6.03
51–60 28 6989 4474 0.003
b 96.9 28.78 0.076
b 17.7 20.69 0.612
b 4.27 3.68 0.444
b 29.36 4.12 0.003
b
61–70 102 7812 5739 0.005
c 99.35 31.06 0.095
c 14.45 21.99 0.108
c 4.35 3.39 0.231
c 28.57 6.07 0.012
c
71–80 146 8671 5486 91.21 36.09 14.77 24.94 4.81 3.84 27.2 5.13
81–91 55 11250 7884 83.39 41.76 13.2 22.74 5.42 3.88 25.44 4.33
AJCC (N total¼343)
I 69 9965 6382 94.96 37.14 13 16.35 4.83 3.24 27.37 7.36
IIA 115 8588 5922 93.16 37.25 14.41 21.69 4.39 3.47 27.92 4.64
IIB 29 7289 5097 0.148
b 102.91 31.73 0.699
b 19.57 30.36 0.873
b 5.98 4.38 0.586
b 27.71 5.48 0.956
b
IIIA 9 6945 6117 0.082
c 86.4 19.76 0.208
c 13.1 18.17 0.93
c 4.06 3.12 0.775
c 26.7 4.68 0.892
c
IIIB 71 8322 5607 90.72 33.58 17.3 30.78 4.7 3.84 27.28 5.19
IIIC 36 9338 7687 92.93 37.94 14.18 23.55 4.71 4.32 27.04 3.84
IV 14 5672 3448 84.42 33.62 13.22 19.87 4.7 3.69 28.35 5.29
T stage (N total¼342)
T1 28 9455 6342 94.68 35.45 17.08 17.81 5.43 3.83 28.3 5.49
T2 59 8927 6292 0.811
b 93.52 35.73 0.989
b 11.16 16.02 0.534
b 4.35 2.77 0.654
b 27.05 7.71 0.443
b
T3 182 8583 6091 0.336
c 92.79 36.14 0.735
c 15.36 24.51 0.842
c 4.73 3.81 0.463
c 27.9 4.7 0.374
c
T4 73 8243 5791 92.18 34.01 16.77 28.75 4.69 3.99 26.89 4.84
N stage (N total¼337)
N0 214 8918 5997 0.449
b 94.63 36.66 0.577
b 14.62 21.52 0.703
b 4.74 3.56 0.985
b 27.73 5.75 0.736
b
N1 79 7907 5467 0.82
c 90 32.53 0.577
c 16.84 30 0.776
c 4.66 3.9 0.925
c 27.29 5.32 0.539
c
N2 44 8666 7258 91.34 35.39 13.47 21.75 4.68 4.07 27.16 3.77
Grade (N total¼245)
1 8 10699 8464 0.563
b 89.7 25.03 0.207
b 10.39 13.76 0.231
b 3.62 2.14 0.463
b 23.97 5.18 0.071
b
2 176 9105 5645 0.998
c 96.81 36.67 0.812
c 17.11 26.21 0.691
c 4.92 3.94 0.394
c 27.73 5.6 0.249
c
3 58 8670 5676 87.13 39.43 11.57 14.86 4.57 2.95 26.84 4.33
Lymph/vascular invasion (N total¼337)
No 236 8724 6099 0.938
a 94.21 34.52 0.373
a 14.08 21.87 0.505
a 4.69 3.54 0.977
a 27.56 5.55 0.71
a
Yes 101 8668 6048 90.44 37.71 15.92 26 4.68 3.96 27.31 4.95
Perineural invasion (N total¼159)
No 135 7023 5870 0.027
a 94.69 32.84 0.609
a 13.05 22.93 0.94
a 4.18 3.34 0.928
a 28.06 5.44 0.887
a
Yes 17 5099 2755 90.37 32.46 12.61 18.35 4.1 2.59 27.85 6.76
Necrosis (N total¼180)
No 142 9645 5574 0.351
a 94.38 38.89 0.77
a 16.26 22.53 0.915
a 5.08 3.91 0.81
a 27.64 4.82 0.918
a
Yes 38 8707 5152 92.34 34.39 15.81 27.05 4.91 4.19 27.54 5.81
Lymphocytic infiltrate (N total¼267)
No 92 7527 4346 95.01 37.05 0.617
b 14.06 25.53 0.62
b 4.03 3.13 0.234
b 27.46 4.7
1 112 9838 5737 0.014
b 91.17 33.96 0.923
c 16.37 24.45 0.605
c 5.06 3.93 0.907
c 27.27 5.85 0.928
b
2 49 9638 6135 0.074
c 87.69 33.65 18.19 26.79 4.72 3.82 27.05 4.94 0.521
c
3 14 10497 8107 97.15 32.16 9.67 16.24 4.27 3.26 26.46 5.43
Abbreviations: AJCC¼American Joint Committee on Cancer; ANOVA¼analysis of variance; BMI¼body mass index; IGF-1¼insulin-like growth factor-1.
aIndependent-samples
t-test.
bOne-way ANOVA.
cTest for linear trend.
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s(Po0.001; P¼0.002, excluding stage IV) had a significantly worse
outcome (Figure 1A and B). High serum VEGF-A was also
associated with poorer survival (P¼0.053; P¼0.041 excluding
stage IV) (Figure 1C). As expected, tumour AJCC stage, T stage,
N stage, lymphatic and vascular invasion, and perineural invasion
were significantly associated with patient survival (Po0.01, data
not shown). The BMI did not significantly affect survival (P¼0.35,
data not shown). No association was shown between type 2
diabetes and survival (n¼28, P¼0.26).
A separate survival analysis was also completed for patients with
AJCC stage II cancer (stages IIA and IIB). The CRP remained a
significant predictor of outcome within this group (P¼0.04,
Figure 1D), whereas Ang-2, T stage, lymphatic and vascular
invasion, and perineural invasion were not significant predictors
of survival in this sub-cohort (data not shown).
Cox regression analysis of individual predictors showed that
VEGF-A, Ang-2 and CRP were significant predictors of overall
survival for the whole cohort (Po0.001; Table 4). These three
predictors were further analysed together in a multivariable model,
in which VEGF-A and Ang-2 remained significant predictors,
whereas CRP was not significant (Table 4, model 1). After
adjusting for tumour stage and age, both VEGF-A and CRP lost
their predictive value and Ang-2 remained the only significant
predictor of survival (Table 4, model 2).
DISCUSSION
This study demonstrated strong associations of markers of
angiogenesis and inflammation with cancer progression and
patient survival in a cohort of 344 colorectal cancer patients.
Serum levels of Ang-2 emerged as strongly predictive of overall
survival in our multivariable survival analysis. Angiopoietin-2
regulates tumour angiogenesis (Ahmad et al, 2001a,b; Sarraf-Yazdi
et al, 2008), and increased levels of tumour Ang-2 are associated
with more aggressive, angiogenic CRC tumours (Chung et al,
2006). The positive correlations observed between serum Ang-2
and serum C-peptide (a stable marker of circulating insulin levels),
and between VEGF-A and IGF-1 in males, may implicate insulin
and IGF-1 in promoting a systemic pro-angiogenic environment,
and potentially increasing tumour angiogenesis.
Prevalence of insulin resistance and type 2 diabetes varies
markedly by age, as well as ethnicity. In individuals aged 460
years, the prevalence of diagnosed diabetes in New Zealand is 9.5%
for Europeans, and 21.0% and 24.5% for Ma ¯ori and Pacific Island
people, respectively (Ministry of Health, 2007). The ethnic
breakdown of this clinical cohort reflects that of the Canterbury
background population, which is predominantly European (77.4%
European, 7.2% Ma ¯ori) (Morrin et al, 2005; Census, 2006). The
prevalence of diagnosed type 2 diabetes was 8.1% in this colorectal
cancer cohort, reflecting that of the background population. Our
study did not find a direct relationship between type 2 diabetes and
colorectal cancer, but the total number with diabetes was relatively
small.
It is now well established that obesity is characterised by chronic
inflammation (Greenberg and Obin, 2006; Park et al, 2010), with
associated increases of CRP, interleukin-6 (IL-6) and plasminogen
activator inhibitor (Dandona et al, 2004). Recent in vivo data in
dietary and genetically obese mouse models demonstrated obesity-
related liver inflammation and subsequent release of IL-6 and
TNFa (Park et al, 2010). Our clinical data supports a significant
association between Ang-2 and inflammation, via the acute phase
inflammatory protein, CRP. This association is supported by
in vitro data (Bello et al, 2008; Turu et al, 2008; Porta et al, 2009)
and recent data from an Ang-2 knock-out mouse model, where lack
of Ang-2 reduced inflammatory bowel disease (Ganta et al, 2010).
However, CRP may also mediate inhibition of angiogenesis, as
shown in vitro (Yang et al, 2005). Our clinical findings suggest that
the influence of inflammation on colorectal cancer progression and
outcome may involve Ang-2-mediated pathways. To support these
Table 3 Associations of angiogenic, inflammation and obesity-related factors in colorectal cancer patients
VEGF-A
(N¼344)
Ang-2
(N¼344)
Adiponectin
(N¼344)
CRP
(N¼344)
IGF-1
(N¼344)
Insulin
(N¼344)
C-peptide
(N¼344)
Ang-2 (N¼344)
Pearson’s correlation 0.19
P-value 0.000
Adiponectin (N¼344)
Pearson’s correlation  0.04 0.05
P-value 0.441 0.314
CRP (N¼344)
Pearson’s correlation 0.23 0.43  0.02
P-value 0.000 0.000 0.788
IGF-1 (N¼344)
Pearson’s correlation 0.10  0.01  0.21  0.18
P-value 0.066 0.894 0.000 0.001
Insulin (N¼344)
Pearson’s correlation 0.03 0.02  0.18  0.08 0.14
P-value 0.587 0.679 0.001 0.142 0.010
C-peptide (N¼344)
Pearson’s correlation 0.02 0.14  0.14  0.02 0.14 0.63
P-value 0.738 0.007 0.010 0.690 0.010 0.000
BMI (N¼318)
Pearson’s correlation 0.04  0.03  0.32 0.07 0.09 0.21 0.27
P-value 0.448 0.542 0.000 0.241 0.105 0.000 0.000
Abbreviations: Ang-2¼angiopoietin-2; BMI¼body mass index; CRP¼C-reactive protein; IGF-1¼insulin-like growth factor-1; VEGF-A¼vascular endothelial growth factor-A.
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sobservations, markers of angiogenesis are being investigated in
tumour samples from this patient cohort.
In our study, serum levels of Ang-2 were a stronger predictor of
survival than serum levels of VEGF-A, the principal angiogenic
factor associated with poor outcome in colorectal cancer (Cao
et al, 2009). Circulating levels of Ang-2 have been shown to
correlate with poor patient survival in other cancers including
melanoma and lung cancer (Park et al, 2007; Helfrich et al, 2009),
and patients with metastatic colorectal cancer have higher levels of
serum Ang-2 than healthy controls (Goede et al, 2010). Angio-
poietin-2 regulates vascular remodelling and endothelial respon-
siveness to pro-inflammatory cytokines (Fiedler et al, 2006). In
addition, recent in vitro and in vivo studies have demonstrated
that Ang-2 acts as a chemoattractant for pro-angiogenic Tie2-
expressing monocyte/macrophages (TEM), and stimulates TEM
to express tumour-promoting factors. Mice with Ang-2 over-
expressed in tumour vasculature had high serum Ang-2 levels,
increased TEM infiltration of tumours and an increased number of
tumour microvessels with immature phenotype (Murdoch et al,
2007; Coffelt et al, 2010). Thus, high levels of Ang-2 may impact
patient survival by facilitating tumour vascular disruption, and by
skewing tumour-infiltrating leukocytes towards an alternatively
activated (M2) phenotype that promotes tumour angiogenesis and
progression.
Experimental and epidemiological studies support the concept
that chronic inflammation has cancer-promoting properties
(Mantovani et al, 2008; Porta et al, 2009). In our study, elevated
serum CRP levels were positively associated with markers of more
advanced disease and worse overall patient survival, consistent
with other studies (Nozoe et al, 1998, 2008). In these studies, CRP
levels above the upper limit of normal of 5mgl
–1 (Nozoe et al,
2008) or 8mgl
–1 (Nozoe et al, 1998) were considered elevated.
However, in cardiovascular disease, CRP is an established risk
factor at levels as low as 0.49mgl
–1 (Ridker et al, 2002), and no
such threshold has yet been determined for cancer. Therefore, in
our study, CRP levels were treated as a continuous variable, and
median (4.1mgl
–1) was used as a cut point between low and high
levels of CRP.
The CRP was the only significant predictor of overall survival in
our sub-cohort of 144 AJCC stage II patients in a multivariable
analysis. While clinical factors are currently used to identify stage
II patients who have a poor prognosis and hence require adjuvant
chemotherapy, a predictive serum biomarker would be of direct
clinical utility. Although Nozoe et al (2008) reported CRP to be
prognostic in a group of 116 patients with all Dukes stages, only 34
had Dukes B disease. Our data suggest that CRP could be used to
support decisions about adjuvant chemotherapy, but would need
further testing in stage II patients.
Associations between CRP and other surrogate markers of
obesity were not significant in this study, although this link is
supported in the literature (Koukourakis et al, 2009; Nguyen et al,
2009). A limitation of our study may be the decision to measure
CRP at diagnosis, which may have obscured the contribution from
obesity, as inflammation within the primary tumour may have
been the main contributor to high serum CRP. This is supported
by the increase in CRP with T stage. A large study in healthy adults
across the weight spectrum in the United States, found a direct
correlation between serum CRP levels and increasing BMI (Nguyen
et al, 2009). A similar correlation was observed in cancer patients
with no detectable tumour, but was lost in cancer patients with
evident cancer burden (Koukourakis et al, 2009). Together with
our data, this suggests that CRP from inflammation in advanced
cancer may obscure that from obesity-related inflammation.
None of the markers of obesity (BMI and serum markers)
showed an association with tumour progression or patient
survival, for the whole cohort, or by gender. The relationship
P-value = 0.001
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Figure 1 Survival of colorectal cancer patients from surgery to death from any cause by Kaplan–Meier survival analysis. Survival between groups with high
and low serum (A) CRP, (B) Ang-2 and (C) VEGF-A. (D) Survival of patients with AJCC stage II disease between groups with high and low serum CRP.
Median values were used as cut points for high vs low values.
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sbetween obesity and patient survival remains equivocal. In a
study of over 4000 colorectal cancer patients, morbidly obese
patients were 40% more likely to have a recurrence or secondary
tumour, and 30% more likely to die, compared with patients with
normal BMI (Dignam et al, 2006). In contrast, a similar sized study
showed no difference in overall, disease-free (DFS) or recurrent-
free survival across all BMI groups (Meyerhardt et al, 2003), except
that obese women younger than 50 years of age had a worse
outcome compared with women with normal BMI. Our cohort
were an older population, with 96% of patients over 50 years of age
and only six women o50 years old. Our study did not determine
waist circumference, and a recent, smaller study (Haydon et al,
2006) found that waist circumference, but not BMI, was associated
with survival. A subsequent study by Meyerhardt found that
morbidly obese patients had decreased DFS, but not overall
survival (Meyerhardt et al, 2008). Only 6.9% of patients in our
study were morbidly obese, and they could not be analysed
separately. The distribution of BMI categories in our study (25.1%
4BMI 30) compared well with other studies (17.5–34.0% 430
BMI) (Dignam et al, 2006; Reeves et al, 2007; Meyerhardt et al,
2008). Hence, current data suggest that severe obesity, rather than
a continuum of BMI, impacts negatively on survival from
colorectal cancer.
Owing to the proven unreliability of BMI as a marker of obesity,
our study sought to define surrogate serum markers of obesity.
While total serum levels of adiponectin and IGF-1 were measured,
our assay system was unable to distinguish high molecular weight
multimers of adiponectin, which represent the most biologically
active form (Kadowaki et al, 2006), and may have better predictive
value. In addition, the IGF-binding proteins, which regulate
bioavailable levels of IGF-1 in circulation (Fuchs et al, 2008), were
not measured. Despite these limitations, our study demonstrated a
consistent and significant relationship among the serum markers
of obesity measured (insulin, C-peptide, IGF-1, adiponectin, BMI),
supporting the conclusion of a limited relationship between
obesity and colorectal cancer survival. We, therefore, propose that
the influence of obesity on tumour progression and survival in
colorectal cancer may be due to obesity-related inflammation,
rather than factors associated with obesity per se.
We have reported serum markers of obesity, inflammation and
angiogenesis at diagnosis of colorectal cancer, and correlated them
with clinicopathological variables and with outcome. We did not
confirm a worse outcome from diagnosis for obese patients, or for
type 2 diabetes, although this conclusion may be limited by small
numbers. Highly sensitive CRP, a marker of inflammation, was
associated with survival, increased with tumour stage and may
have reflected inflammation in the tumour as well as that due to
obesity. We have established the value of the pro-angiogenic factor
Ang-2 in serum to predict survival. We have shown an association
between obesity, inflammation, angiogenesis and outcome, but not
demonstrated a role of the insulin-IGF-1 axis. However, the
possible effects of obesity and insulin-IGF-1 on response to
chemotherapy treatment warrant further study.
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